Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"EpiPharm","sponsor":"CycloLab Cyclodextrin Research and Development Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclolab and EpiPharma Form Joint Venture Company Targetrin Therapeutics to Develop Conjugated Cyclodextrin Peptide Drugs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Peptide","graph2":"EpiPharm"},{"company":"Synendos Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","amount":"$22.4 million","upfrontCash":"Undisclosed","newsHeadline":"Synendos Therapeutics Raises CHF 20 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Synendos Therapeutics"},{"company":"Asceneuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer's and Parkinson's Disease Models","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Asceneuron"},{"company":"Asceneuron","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson's Disease Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Asceneuron"},{"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AC Immune"},{"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AC Immune"}]

Asceneuron

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson's Disease Therapies

Details:

The grant will fund a preclinical proof-of-concept study to assess the disease-modifying properties of Asceneuron’s OGA inhibitor ASN51 in a preclinical model of inherited PD.

Lead Product(s): ASN51

Therapeutic Area: Neurology Product Name: ASN51

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson’s Research

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding May 03, 2022

ASK
US

Upload
your Pipeline Activity

Asceneuron

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer's and Parkinson's Disease Models

Details:

Findings published demonstrated increased survival in preclinical model of Alzheimer's disease after administration of clinical molecule ASN90, an O–GlcNAcase inhibitor, as well as significant motor impairment and astrogliosis effect in a Parkinson's model.

Lead Product(s): ASN90

Therapeutic Area: Neurology Product Name: ASN90

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2022

ASK
US

Upload
your Pipeline Activity

AC Immune

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

Details:

Data from the Company’s wholly owned, first-in-class therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) are described during four oral and e-poster presentations.

Lead Product(s): Anti alpha-synuclein antibody

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2021

ASK
US

Upload
your Pipeline Activity

EpiPharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cyclolab and EpiPharma Form Joint Venture Company Targetrin Therapeutics to Develop Conjugated Cyclodextrin Peptide Drugs

Details:

Cyclolab and EpiPharma have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.

Lead Product(s): Conjugated cyclodextrin-peptide therapies

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: CycloLab Cyclodextrin Research and Development Laboratory

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 11, 2021

ASK
US

Upload
your Pipeline Activity

Synendos Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Synendos Therapeutics Raises CHF 20 Million in Series A Financing

Details:

Financing will allow Synendos Therapeutics to complete pre-clinical development and progress lead candidate through proof of concept clinical study.

Lead Product(s): SYT-510

Therapeutic Area: Neurology Product Name: SYT-510

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Kurma Partners

Deal Size: $22.4 million Upfront Cash: Undisclosed

Deal Type: Series A Financing November 12, 2020

ASK
US

Upload
your Pipeline Activity

AC Immune

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

Details:

Advancing anti-TDP-43 antibody towards clinical development is latest in series of important milestones already achieved this year in the Company’s cutting-edge therapeutic and diagnostic programs targeting TDP-43.

Lead Product(s): Anti-TDP-43 antibody

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY